source
- Ultragenyx to lay off roughly 20% of staff as it halts two rare disease drug programsUltragenyx announced it will cut about 20% of its workforce as it ends development of two rare disease drug candidates. The move follows a recent clinical study that failed to meet its primary end…
- First wave of ASH 2026 abstracts released, featuring data from J&J, Servier and AstraZenecaThe American Society of Hematology’s annual meeting is set for New Orleans, Louisiana, a little over a month away. The first batch of abstracts for the conference has been posted, showcasing early…